Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 109

1.

Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis.

Ollech JE, Dwadasi S, Rai V, Peleg N, Normatov I, Israel A, Sossenheimer PH, Christensen B, Pekow J, Dalal SR, Sakuraba A, Cohen RD, Rubin DT.

Aliment Pharmacol Ther. 2019 Dec 25. doi: 10.1111/apt.15616. [Epub ahead of print]

PMID:
31875986
2.

The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-Marketing Data.

Cohen RD, Bhayat F, Blake A, Travis S.

J Crohns Colitis. 2019 Aug 13. pii: jjz137. doi: 10.1093/ecco-jcc/jjz137. [Epub ahead of print]

PMID:
31504340
3.

Follow-Up of Patients With Ulcerative Colitis and Histological Normalization.

Israel A, Christensen B, El Jurdi K, Rai V, Ollech JE, Cohen RD, Sakuraba A, Dalal SR, Rubin DT.

Clin Gastroenterol Hepatol. 2019 Jun 20. pii: S1542-3565(19)30663-9. doi: 10.1016/j.cgh.2019.06.025. [Epub ahead of print]

PMID:
31228567
4.

Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis.

Ollech JE, Rubin DT, Glick L, Weisshof R, El Jurdi K, Israel A, Krugliak Cleveland N, Hyman N, Sakuraba A, Pekow J, Cohen RD, Dalal SR.

Dig Dis Sci. 2019 Dec;64(12):3596-3601. doi: 10.1007/s10620-019-05697-1. Epub 2019 Jun 11.

5.

Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.

Wang Y, Wang J, Pekow J, Dalal S, Cohen RD, Ollech J, Israel A, Shogan BD, Micic D, Cannon L, Umanskiy K, Hurst R, Hyman N, Rubin DT, Sakuraba A.

J Gastroenterol Hepatol. 2019 Dec;34(12):2090-2095. doi: 10.1111/jgh.14751. Epub 2019 Jun 28.

PMID:
31169926
6.

Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers.

Alpert L, Yassan L, Poon R, Kadri S, Niu N, Patil SA, Mujacic I, Montes D, Galbo F, Wurst MN, Zhen CJ, Cohen RD, Rubin DT, Pekow JR, Weber CR, Xiao SY, Hart J, Segal J, Setia N.

Hum Pathol. 2019 Jul;89:44-50. doi: 10.1016/j.humpath.2019.04.013. Epub 2019 May 2.

PMID:
31054900
7.

Maneuvering Clinical Pathways for Crohn's Disease.

Lu TX, Cohen RD.

Curr Gastroenterol Rep. 2019 Apr 23;21(5):20. doi: 10.1007/s11894-019-0687-4. Review.

PMID:
31016466
8.

Low-Dose Metronidazole is Associated With a Decreased Rate of Endoscopic Recurrence of Crohn's Disease After Ileal Resection: A Retrospective Cohort Study.

Glick LR, Sossenheimer PH, Ollech JE, Cohen RD, Hyman NH, Hurst RD, Rubin DT.

J Crohns Colitis. 2019 Sep 19;13(9):1158-1162. doi: 10.1093/ecco-jcc/jjz047.

PMID:
30809655
9.

Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease.

Ollech JE, Aharoni-Golan M, Weisshof R, Normatov I, Sapp AR, Kalakonda A, Israel A, Glick LR, Karrison T, Dalal SR, Sakuraba A, Cohen RD, Rubin DT, Pekow J.

Gastrointest Endosc. 2019 Aug;90(2):269-275. doi: 10.1016/j.gie.2019.01.029. Epub 2019 Feb 6.

10.

Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe.

Weisshof R, Ollech JE, El Jurdi K, Yvellez OV, Cohen RD, Sakuraba A, Dalal S, Pekow J, Rubin DT.

J Crohns Colitis. 2019 Sep 19;13(9):1105-1110. doi: 10.1093/ecco-jcc/jjz032.

PMID:
30726894
11.

Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies.

Frohne CC, Llano EM, Perkovic A, Cohen RD, Luke JJ.

J Immunother Cancer. 2019 Jan 6;7(1):1. doi: 10.1186/s40425-018-0484-x.

12.

Abnormal Pouchogram Predicts Pouch Failure Even in Asymptomatic Patients.

Sossenheimer PH, Glick LR, Dachman AH, Skowron KB, Rubin MA, Umanskiy K, Smith R, Cannon LM, Hurst RD, Cohen RD, Hyman NH, Rubin DT.

Dis Colon Rectum. 2019 Apr;62(4):463-469. doi: 10.1097/DCR.0000000000001285.

PMID:
30540661
13.

Early Clinical Outcomes of a New Cementless Total Knee Arthroplasty Design.

Cohen RG, Sherman NC, James SL.

Orthopedics. 2018 Nov 1;41(6):e765-e771. doi: 10.3928/01477447-20180828-05. Epub 2018 Sep 5.

PMID:
30168838
14.

Correction to: Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study.

Micic D, Yarur A, Gonsalves A, Rao VL, Broadaway S, Cohen R, Dalal S, Gaetano JN, Glick LR, Hirsch A, Pekow J, Sakuraba A, Walk ST, Rubin DT.

Dig Dis Sci. 2018 Oct;63(10):2815. doi: 10.1007/s10620-018-5249-3.

PMID:
30136047
15.

A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease.

Anyane-Yeboa A, Yamada A, Haider H, Wang Y, Komaki Y, Komaki F, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Hurst R, Hyman N, Rubin DT, Sakuraba A.

Aliment Pharmacol Ther. 2018 Nov;48(9):933-940. doi: 10.1111/apt.14951. Epub 2018 Aug 20.

16.

Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report.

Lichtenstein GR, Feagan BG, Mahadevan U, Salzberg BA, Langholff W, Morgan JG, Safdi M, Nissinen R, Taillard F, Sandborn WJ, Cohen RD.

Am J Gastroenterol. 2018 Nov;113(11):1678-1688. doi: 10.1038/s41395-018-0202-9. Epub 2018 Jul 19.

PMID:
30022113
17.

Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia.

Krugliak Cleveland N, Ollech JE, Colman RJ, Rodriquez D, Hirsch A, Cohen RD, Hanauer SB, Hart J, Hurst R, Rubin DT.

Clin Gastroenterol Hepatol. 2019 Jan;17(1):205-206. doi: 10.1016/j.cgh.2018.04.061. Epub 2018 May 8.

PMID:
29751167
18.

Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.

Christensen B, Gibson PR, Micic D, Colman RJ, Goeppinger SR, Kassim O, Yarur A, Weber CR, Cohen RD, Rubin DT.

Clin Gastroenterol Hepatol. 2019 Feb;17(3):486-493. doi: 10.1016/j.cgh.2018.04.060. Epub 2018 May 8.

PMID:
29751166
19.

Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety.

Christensen B, Colman RJ, Micic D, Gibson PR, Goeppinger SR, Yarur A, Weber CR, Cohen RD, Rubin DT.

Inflamm Bowel Dis. 2018 Mar 19;24(4):849-860. doi: 10.1093/ibd/izx067.

20.

Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy.

Patel P, Yarur A, Dalal S, Sakuraba A, Rubin DT, Hanauer SB, Hanan I, Raffals LH, Cohen RD, Pekow J.

Inflamm Bowel Dis. 2018 May 18;24(6):1291-1297. doi: 10.1093/ibd/izx105.

PMID:
29506124

Supplemental Content

Loading ...
Support Center